Skip to main content
Premium Trial:

Request an Annual Quote

Roche Cobas HIV-1, HCV, and HCV Genotyping

Roche will make its Cobas HIV-1, hepatitis C virus, and HCV genotyping assays commercially available in countries accepting the CE mark, the firm announced today. The three assays can run simultaneously on the Cobas 4800 PCR system, which performs automated nucleic acid purification, PCR set-up, real-time amplification, and detection. The assays were CE-marked in December of last year, and add to a menu on the Cobas 4800 that also includes nine other in vitro diagnostic tests for infectious diseases and cancer-related mutations.

The dual-target HIV-1 assay amplifies two regions of the genome that are not subject to selective drug pressure, enabling more effective quantification of HIV-1 RNA in patient samples. The HCV detection assay is a dual-probe test to confirm active infection or assess response to antiviral therapy, while the HCV genotyping test identifies genotypes 1 to 6 as well as genotype 1 subtypes a and b in plasma or serum from chronically infected patients.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.